Bruker BRKR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bruker in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bruker's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bruker's cash & equivalents?
- Bruker (BRKR) reported cash & equivalents of $137.6M in Q1 2026.
- How has Bruker's cash & equivalents changed year-over-year?
- Bruker's cash & equivalents decreased by 26.7% year-over-year, from $187.7M to $137.6M.
- What is the long-term trend for Bruker's cash & equivalents?
- Over 5 years (2020 to 2025), Bruker's cash & equivalents has grown at a -15.1% compound annual growth rate (CAGR), from $685.5M to $303.1M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid short-term investments held by the company.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for M&A or R&D investment, while a decrease may indicate heavy capital expenditure or cash burn.
- How does cash & equivalents compare across companies?
- Peers in the life sciences sector typically maintain cash levels sufficient to cover 6-12 months of operating expenses.